Skip to content
Search
Facebook
 
ADCSADCS
ADCS
Alzheimer's Disease Cooperative Study
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources
  • Currently Enrolling Studies
  • Active (Not Enrolling)
  • Closed Studies

Currently Enrolling Studies

VIVA-MIND Study

The VIVA-MIND trial is designed to determine if the study drug, varoglutamstat, can stabilize or slow memory and thinking problems that increase in early AD.

Active (Not Enrolling)

3 Star Study

The 3 Star Study will research and test whether an investigational vaccine can affect Alzheimer’s disease-related brain changes in participants with Down Syndrome.The 3 Star Study is designed for individuals who have Down Syndrome, are 25-45 years of age, do not have any other serious illness, and have a caregiver or informant who can answer questions about them.

T2 Protect AD

T2 is designed to determine if troriluzole can protect, slow down, or potentially improve memory and thinking problems that increase as Alzheimer’s disease progresses. 

Discover Study

The Discover Study is a randomized, double-blind, placebo controlled study. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).

Peace-AD Study

PEACE-AD is a multicenter, randomized, placebo-controlled study evaluating the efficacy and safety of the Prazosin drug.

UC Cures SALAD Study

SALAD is a Phase 1b, 12-month, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of salsalate in patients with mild to moderate Alzheimer’s disease. 

UC Cures NEAT Study

NEAT is a Phase 2, proof of concept, double-blind, randomized, placebo-controlled adaptive design trial of Nicotinamide in MCI due to AD and Mild AD Dementia.

 

EXERT Study

The EXERT study is a national, 18-month long, clinical trial to test whether physical exercise can slow the progression of mild memory loss and/or mild cognitive impairment in older adults between the ages of 65-89.

Closed Studies

NOBLE Study

NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer’s disease. The investigational drug may work by protecting brain cells, which could result in improved memory. The study will determine whether the drug is efficacious.

Resveratrol Study

A Phase II clinical study of Resveratrol (RES) designed to evaluate the safety, tolerability and effectiveness of Resveratrol on cerebrospinal fluid and other biomarkers for the treatment of Alzheimer’s disease.

Home-Based Assessments Study

Evaluate three methods of performing home-based assessments in an Alzheimer’s disease prevention trial.

Nerve Growth Factor Study

Ceregene’s CERE-110 gene therapy product designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer’s disease is currently underway.

ADNI Study

Determine whether imaging of the brain every six months can help predict the onset of Alzheimer’s disease, and monitor the progression of the disease as well.

Gammaglobulin Alzheimer’s Partnership Study

Further examination of the safety, effectiveness and tolerability of IVIg in mild to moderate Alzheimer’s Disease patients.

Docosahexaenoic Acid (DHA) Study

A randomized, double-blind, placebo-controlled trial of the effects of Docosahexaenoic Acid (DHA) in slowing the progression of Alzheimer’s disease.

Valproate Neuroprotection (VN) Study

Determine whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer’s disease who have not experienced agitation and psychosis in their illness.

RAGE Inhibitor (RI) Study

The experimental drug in this study may block a critical pathway in Alzheimer’s disease that causes damage to the nerve cells in the brain.

Huperzine A (HU) Study

A multicenter, double-blind, placebo-controlled therapeutic trial to determine whether natural huperzine A improves cognitive function in Alzheimer’s disease.

About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

FacebookRssMail
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
Copyright 2017 Regents of the University of California.